Dr. Matthew H. Kulke Talks About Telotristat Etiprate Benefitting Carcinoid Syndrome Patients
Matthew H. Kulke, MD, director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute in Boston, talks about the strong potential of telotristat etiprate, a novel serotonin synthesis inhibitor.
Matthew H. Kulke, MD, director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute in Boston, talks about the strong potential of telotristat etiprate, a novel serotonin synthesis inhibitor.
Kulke says telotristat etiprate could potentially represent a new class of treatment for patients with carcinoid syndrome, due to its ability to decrease serotonin levels. He adds that serotonin levels could present a problem for patients with carcinoid syndrome and lower levels may help avoid heart disease and fibrosis of the intestines.
Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma
October 7th 2024A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.
Read More
